Gastroenterology
Volume 138, Issue 7 , Pages 2348-2356 , June 2010

Low Bone Mass and Severity of Cholestasis Affect Fracture Risk in Patients With Primary Biliary Cirrhosis

  • Núria Guañabens

      Affiliations

    • Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
    • CIBERehd, Barcelona, Spain
    • Corresponding Author InformationReprint requests Address requests for reprints to: Núria Guañabens, Service of Rheumatology, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain
    • ,
  • Dacia Cerdá

      Affiliations

    • Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
    • ,
  • Ana Monegal

      Affiliations

    • Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
    • ,
  • Francesca Pons

      Affiliations

    • Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
    • ,
  • Llorenç Caballería

      Affiliations

    • CIBERehd, Barcelona, Spain
    • Liver Unit, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
    • ,
  • Pilar Peris

      Affiliations

    • Metabolic Bone Diseases Unit, Service of Rheumatology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
    • CIBERehd, Barcelona, Spain
    • ,
  • Albert Parés

      Affiliations

    • CIBERehd, Barcelona, Spain
    • Liver Unit, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain

Received 16 November 2009 ,Accepted 9 February 2010.

References 

  1. Parés A, Guañabens N. Treatment of bone disorders in liver disease. J Hepatol. 2006;45:445–453
  2. Guañabens N, Parés A, Mariñoso L, et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol. 1990;85:1356–1362
  3. Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-contolled trial. Hepatology. 2005;42:762–771
  4. Newton J, Francis R, Prince M, et al. Osteoporosis in primary biliary cirrhosis revisited. Gut. 2001;49:282–287
  5. Guañabens N, Parés A, Ros I, et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol. 2005;42:573–577
  6. Boulton-Jones JR, Fenn RMF, West J, et al. Fracture risk of women with primary biliary cirrhosis: no increase compared with general population controls. Aliment Pharmacol Ther. 2004;20:551–557
  7. Solayman-Dodaran M, Card TR, Aithal GP, et al. Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology. 2006;131:1752–1757
  8. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185–1194
  9. Brown JP, Fortier M. Canadian Consensus Conference on Osteoporosis, 2006 Update. JOGC. 2006;172:S95–S112
  10. Cheung AM, Detsky AS. Osteoporosis and fractures (Missing the bridge?). JAMA. 2008;299:1468–1470
  11. Garnero P, Delmas PD. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. Musculoskel Neuron Interact. 2004;4:50–63
  12. Roux C, Briot K, Horlait S, et al. Assessment of non-vertebral fracture risk in postmenopausal women. Ann Rheum Dis. 2007;66:931–935
  13. Ludwig J, Dickson ER, McDonald SA. Staging of chronic non-suppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Path Anat Histol. 1978;379:103–110
  14. World Health Organization Study Group. assessment of fracture risk and its application to screening for postmenopausal osteoporosis (WHO technical report series 843). In: Geneva: WHO; 1994;p. 2–25
  15. Diaz Curiel M, Garcia JJ, Carrasco JL, et al. Prevalencia de osteoporosis determinada por densitometría en la población española. Med Clin (Barc). 2001;116:86–88
  16. Jonhell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005;16(Suppl 2):S3–S7
  17. Harvey N, Dennison E, Cooper C. Epidemiology of osteoporotic fractures. In:  Rosen CJ editors. Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th ed.. Washington, DC: American Society for Bone and Mineral Research; 2006;p. 198–203
  18. Siris E, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women (Results from the National Osteoporosis Risk Assessment). JAMA. 2001;286:2815–2822
  19. Pereira SP, Bray GP, Pitt PI, et al. Non-invasive assessment of bone density in primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 1999;11:323–328
  20. Bagur A, Mautalen C, Findor J, et al. Risk factors for the development of vertebral and total skeleton osteoporosis in patients with primary biliary cirrhosis. Calcif Tissue Int. 1998;63:385–390
  21. Menon KVN, Angulo P, Weston S, et al. Bone disease in primary biliary cirrhosis. J Hepatol. 2001;35:316–323
  22. Guichelar MMJ, Malinchoc M, Sibonga J, et al. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology. 2002;36:895–903
  23. Delmas PD, Marin F, Marcus R, et al. Beyond hip: importance of other nonspinal fractures. Am J Med. 2007;120:381–387
  24. Hodgson SF, Dickson ER, Wahner HW, et al. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med. 1985;103:855–860
  25. Hodgson SF, Dickson ER, Eastell R, et al. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone. 1993;14:819–827
  26. Guichelaar MMJ, Malinchoc M, Sibonga JD, et al. Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease. J Bone Miner Res. 2003;18:2190–2199
  27. Ackerman Z, Weinreb M, Amir G, et al. Bone mineral metabolism and histomorphometry in rats with cholestatic liver disease. Liver. 2002;22:166–172
  28. Smith DLH, Shire NJ, Watts NB, et al. Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease. J Clin Densitom. 2006;9:105–113
  29. Janes CH, Dickson ER, Okazaki R, et al. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest. 1995;95:2581–2586
  30. Ruiz-Gaspá S, Enjuanes A, Guañabens N, et al. Lithocholic acid down-regulates vitamin D effects in human osteoblasts. Eur J Clin Invest. 2010;40:34–35
  31. Ruiz-Gaspà S, Martinez-Ferrer A, Enjuanes A, et al. High bilirubin reduces cell survival and differentiation of primary human osteoblasts (Is this effect applicable to the serum of chronic cholestatic patients?). J Bone Miner Res 24 (Suppl 1) http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=a928a897-3e9d-4dea-a390-433c532b7802Accessed September 17, 2009
  32. Kawelke N, Bentmann A, Hackl N, et al. Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation. J Bone Miner Res. 2008;23:1278–1286
  33. Olivier BJ, Schoenmaker T, Mebius RE, et al. Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia. Hepatology. 2008;47:259–267
  34. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002;50(Suppl 1):1–19

 Conflicts of interest The authors disclose no conflicts.

 Funding Supported, in part, by Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, and FIS-08/0105, Ministerio de Ciencia e Innovación, Spain.

PII: S0016-5085(10)00207-6

doi: 10.1053/j.gastro.2010.02.016

Gastroenterology
Volume 138, Issue 7 , Pages 2348-2356 , June 2010

Article Tools

* Image Usage & Resolution